Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 10,186

Document Document Title
WO/2021/063404A1
A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.  
WO/2021/066873A1
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a ...  
WO/2021/062549A1
The present disclosure relates to redox active materials, such as the compound of formula (I), comprising at least one 2,5-dithio-7- azabicyclo(2.2. l)heptane unit connected to a surface thereof, as well as processes for making said redo...  
WO/2021/067521A1
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...  
WO/2021/067827A1
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.  
WO/2021/062318A1
Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical composition...  
WO/2021/048342A1
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.  
WO/2021/050994A1
Provided herein are heterobicyclic cyclopropanecarboxamide and heterobicyclic carboxamide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or...  
WO/2021/042178A1
This invention relates to methods of treating, preventing, managing and/or controlling opioid withdrawal and/or a symptom associated with the opioid withdrawal. Compounds, compositions, medicaments and kits are provided that may be used ...  
WO/2021/043703A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2021/045469A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.  
WO/2021/043973A1
A compound of compound according to formula (I), wherein X is selected from the group consisting of CH, CCl and N, Z is selected from the group consisting of CH2COOH, CH(CH3)COOH, C(CH3)2COOH and CH2F, D is a single bond connecting A and...  
WO/2021/040310A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element using same.  
WO/2021/038452A1
The present invention relates to compounds having a tetracyclic system and the use thereof as new therapeutic agents in the treatment of acute myeloid leukemia (AML), preferably in FLT3/ITD hemizygote patients resistant to conventional t...  
WO/2021/032588A1
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds ...  
WO/2021/028645A1
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein ac...  
WO/2021/030686A1
The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza- benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I). Furthermore, the present invention prov...  
WO/2021/030554A1
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.  
WO/2021/030556A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...  
WO/2021/030671A1
The present invention includes 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza- benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) or a pharmaceutically acceptable salt thereof for use in trea...  
WO/2021/028649A1
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein ac...  
WO/2021/030278A1
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...  
WO/2021/030552A1
Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same,...  
WO/2021/026109A1
Disclosed are bispecific compounds (degraders) that target CDK7 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.  
WO/2021/026009A1
The present disclosure relates to compounds of formula (IA') as STING (Stimulator of Interferon Genes) agonists for use in the treatment of e.g. cancer, obesity, liver injuries, sugar-lipid metabolism and virus infections. The present de...  
WO/2021/021634A1
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...  
WO/2021/021986A1
The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.  
WO/2021/018194A1
Provided are compounds represented by Formula I, wherein R1, R 2a, R 2b, R 2c, R 2d, R 3, R 4a, R 4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Fo...  
WO/2021/016289A1
Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R1, R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as modulat...  
WO/2021/005043A1
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseas...  
WO/2021/005034A1
The invention provides new heterocyclic compounds having the general formula (I) wherein R1, R2, X, and Y are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...  
WO/2021/005436A1
The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liv...  
WO/2021/001453A1
The present invention is directed to compounds according to Formula (I) and the pharmaceutically acceptable salts thereof. The compounds can be used as modulators of Estrogen-related Receptor alpha (ERRĪ±) and have utility in the treatme...  
WO/2021/001567A1
The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder in a mammalian subject, wherein the T cell has been engineered (i) to overexpress BLIMP1 and/or (ii) to knock-out or decreas...  
WO/2021/000046A1
Described herein is a synergistic combination comprising a quorum-sensing inhibitor and/or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and meth...  
WO/2020/254697A1
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a compo...  
WO/2020/253659A1
Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2020/247054A1
The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.  
WO/2020/247160A1
The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautom...  
WO/2020/247336A1
Disclosed herein are Pifithrin compounds, methods of treating Rett Syndrome, brain fusion organoids comprising a fusion between a cerebral cortex (Cx) organoid and the ganglionic eminence (GE) organoid, one of which comprises, consists e...  
WO/2020/243519A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2020/239025A1
The present subject matter contemplates small molecule, fluorescent compounds having aggregation-induced emission (AIE) characteristics. The compounds can exhibit emission in the second near-infrared window (NIR-II) (1000 nm-1700 nm). Th...  
WO/2020/239074A1
A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.  
WO/2020/243153A1
The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV inf...  
WO/2020/239999A1
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventin...  
WO/2020/239517A1
Mesoionic imidazolium compounds of formula (I) and their uses for combating animal pests. The present invention relates to compounds of formula (I), wherein A, W, Y, T and R1 are defined as in the description, and to the stereoisomers, s...  
WO/2020/232655A1
Presented is an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic elect...  
WO/2020/237169A1
Disclosed herein are compounds, compositions, and methods for inhibiting a histone methyltransferase. The compounds are verticillin derivatives that exhibit anti-proliferative activity against cancer cells. The compounds, compositions, a...  
WO/2020/234483A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/237063A1
A compound with the following general formula (I) and a general method of making this compound are provided. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are each independently selected from the group that includes H, h...  

Matches 1 - 50 out of 10,186